Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double‐blind, placebo‐controlled study

Abstract

At daily doses of 0.5-2.5 mg and 3-6 mg, risperidone was effective and well tolerated in children and adolescents experiencing acute manic or mixed episodes of bipolar I disorder. Results indicate that risperidone 0.5-2.5 mg has a better benefit-risk profile than risperidone 3-6 mg.